Fresenius : Conference Call Q1 2021, Fresenius (PDF, 1.87 MB)

Conference Call │ Q1/21 Results

Bad Homburg, 06 May 2021

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing.

Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Q1/21 Results, 06 May 2021 © Fresenius SE & Co. KGaA Investor Relations & Sustainability

2

Agenda

01

Key messages

02		03		04
Strategic update		Financial review		Outlook FY/21
		Q1/21

Q1/21 Results, 06 May 2021 © Fresenius SE & Co. KGaA Investor Relations & Sustainability

3

Key messages

Good start to the year;

Ongoing decisive efforts to

Cost & efficiency program:

Guidance FY/21 confirmed

robust growth rates despite

combat COVID-19

Savings of at least €100 m

tough prior year comp

p.a. after tax and minorities

in 2023

	Delivers solid first quarter in	Ongoing headwinds in North	Elective treatments in	Q1/21 significantly
		light of COVID-19 pandemic	America whilst Emerging	Germany still on low level;	impacted by COVID-19
				Markets show healthy	activity levels in Spain
				growth	higher than pre-pandemic
					levels
					Q1/21 Results, 06 May 2021 © Fresenius SE & Co. KGaA Investor Relations & Sustainability	4

Agenda

01

Key messages

02

Strategic update

03		04
Financial review		Outlook FY/21
Q1/21

Q1/21 Results, 06 May 2021 © Fresenius SE & Co. KGaA Investor Relations & Sustainability

5